2018年的病毒性肝炎 慢性HBV感染中的宿主 - 病原体相互作用和

StephenW

VIRAL HEPATITIS IN 2018
Host–pathogen interactions in chronic HBV infection and transplantation of HCV-positive organs

    Jordan J. Feld & Adam J. Gehring

Nature Reviews Gastroenterology & Hepatologyvolume 16, pages77–78 (2019) | Download Citation

HBV and HCV infections continue to be major global health problems, causing over 1 million deaths annually. Key studies this year investigated the innate and adaptive immune responses in different clinical scenarios in HBV infection, whereas others evaluated the merits of transplanting HCV-infected organs into uninfected recipients.
Key advances

    HBV is able to act as a ‘stealth virus’ and evade the innate immune response1,2,3.

    Factors associated with hepatitis flares after stopping antiviral therapy could eventually serve as biomarkers to predict who can safely stop treatment5,6.

    Transmission of HCV can occur through liver transplantation despite absence of measurable viraemia in HCV-antibody positive donors, highlighting the need for close follow-up of patients receiving these organs7.

    Organ transplantation from HCV-infected donors to HCV-uninfected recipients is safe but early and possibly even pre-emptive treatment is important to reduce the risk of relapse or severe initial infection8,9.



07 January 2019
DOI

https://doi.org/10.1038/s41575-018-0101-y

桦子

2018年的病毒性肝炎
慢性HBV感染中的宿主 - 病原体相互作用和HCV阳性器官的移植

     Jordan J. Feld和Adam J. Gehring

Nature Reviews Gastroenterology＆Hepatologyvolume 16，pages77-78（2019）|下载引文

HBV和HCV感染仍然是全球主要的健康问题，每年造成100多万人死亡。今年的主要研究调查了HBV感染的不同临床情况下的先天性和适应性免疫反应，而其他人则评估了将HCV感染的器官移植到未感染的受体中的优点。
关键进展

     HBV能够充当“隐形病毒”并逃避先天免疫反应1,2,3。

     停止抗病毒治疗后与肝炎发作相关的因素最终可以作为生物标志物来预测谁可以安全地停止治疗5,6。

     尽管HCV抗体阳性供体缺乏可测量的病毒血症，但HCV的传播可通过肝移植发生，突出了接受这些器官的患者的密切随访需要7。

     从HCV感染的供体到HCV未感染的受体的器官移植是安全的，但早期甚至可能先发制人的治疗对于降低复发或严重初始感染的风险很重要8,9。



2019年1月7日
DOI